PharmaShots Weekly Snapshots (October 07 – October 11, 2024)
This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Biotech, M&A, Biosimilar, Animal Health, Regulatory & MedTech. Check out our full report below:
AstraZeneca Reports the Data from P-IIIb (BATURA) Study of Airsupra (Albuterol/Budesonide) for Intermittent or Mild Persistent Asthma
Read More: AstraZeneca
GE HealthCare Reports the P-I Study Data of its Macrocyclic Manganese-Based MRI Contrast Agent
Read More: GE HealthCare
Hansa Biopharma Reports the Results from the NICE-01 Clinical Evaluation of HNSA-5487
Read More: Hansa Biopharma
BerGenBio Reports the Data from P-Ib/IIa (BGBC016) Clinical Evaluation of Bemcentinib as 1L Treatment of NSCLC
Read More: BerGenBio
Cybrexa Therapeutics Doses the First Patient with CBX-12 Under P-II Study for Treating Ovarian Cancer
Read More: Cybrexa Therapeutics
Sage Therapeutics Provides Data from the P-II (LIGHTWAVE) Trial of Dalzanemdor to Treat Mild Cognitive Impairment and Dementia in Alzheimer’s Disease
Read More: Sage Therapeutics
Merck Provides Update on P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment of Head and Neck Squamous Cell Carcinoma
Read More: Merck
Aurigene Oncology Reports Results from the P-I (SWASTH) Trial of Ribrecabtagene Autoleucel for Multiple Myeloma in India
Read More: Aurigene Oncology
Oncoinvent Reports the First Patient Dosing with Radspherin in its P-II Clinical Evaluation for Ovarian Cancer
Read More: Oncoinvent
Pfizer Reports the Data from P-III (TALAPRO-2) Study of Talzenna Plus Xtandi for Treating mCRPC
Read More: Pfizer
Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials
Read More: Johnson & Johnson
Zealand Pharma and Boehringer Ingelheim Report the US FDA’s Breakthrough Therapy Designation of Survodutide for MASH
Read More: Zealand Pharma and Boehringer Ingelheim
Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients
Read More: Biogen
Roche’s Reports the US FDA’s Approval of Itovebi as a Treatment for HR+ and HER2- breast cancer with a PIK3CA mutation
Read More: Roche
Burning Rock and Dizal Reports China's NMPA Approval of Co-Developed Companion Diagnostic (CDx) for Lung Cancer
Read More: Burning Rock and Dizal
Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications
Read More: Astellas and AviadoBio
Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment
Read More: Boehringer Ingelheim and Circle Pharma
Exact Sciences Reports the US FDA’s Approval of Cologuard Plus Test for Non-Invasive Colorectal Cancer Screening
Read More: Exact Sciences
The US FDA Grants Approval to ALK’s Series of AccuTest Devices for Allergy Testing and Diagnosis
Read More: ALK
Roche’s Ventana CLDN18 (43-14A) RxDx Assay Receives CE Mark Approval to Diagnose G/GEJ Cancer Patients with CLDN18 Protein Expression
Read More: Roche
RIVANNA launches a Global FIH Trial for its Accuro XV Musculoskeletal Imaging System
Read More: RIVANNA
Caldera Medical Reports the Acquisition of UVision360, Strengthening its Minimally Invasive Hysteroscopy Portfolio
Read More: Caldera Medical
Johnson & Johnson Completes the Acquisition of V-Wave
Read More: Johnson & Johnson and V-Wave
Teva Reports the Acceptance of Regulatory Submissions for TVB-009P (Biosimilar, Prolia) by the US FDA and EMA
Read More: Teva Pharmaceuticals
Bio-Thera Collaborates with Gedeon Richter for BAT2206 (Biosimilar, Stelara)
Read More: Bio-Thera and Gedeon Richter
Alvotech Reports the EMA’s Acceptance of MAA for AVT03 (Biosimilar, Prolia and Xgeva)
Read More: Alvotech
Elanco Animal Health Reports the US FDA’s Approval of Credelio Quattro for Protection Against Parasites in Dogs
Read More: Elanco Animal Health
AstraZeneca Inks a Pact with CSPC Pharmaceutical Group to Advance a Lipid-Lowering Pre-Clinical Candidate
Read More: AstraZeneca and CSPC Pharmaceutical
Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program
Read More: Bayer and MOMA Therapeutics
Revalesio Reports Results from its Non-Clinical Study of RNS60 for Amyotrophic Lateral Sclerosis (ALS)
Read More: Revalesio
Related Post: PharmaShots Weekly Snapshots (September 30 – October 04, 2024)
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com